Bicycle Therapeutics (NASDAQ:BCYC) Delivers Shareholders Solid 16% CAGR Over 5 Years, Surging 6.1% in the Last Week Alone
Bicycle Therapeutics (NASDAQ:BCYC) Delivers Shareholders Solid 16% CAGR Over 5 Years, Surging 6.1% in the Last Week Alone
It hasn't been the best quarter for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, since the share price has fallen 12% in that time. But that scarcely detracts from the really solid long term returns generated by the company over five years. It's fair to say most would be happy with 106% the gain in that time. Generally speaking the long term returns will give you a better idea of business quality than short periods can. Of course, that doesn't necessarily mean it's cheap now.
自2020-12-31以來,Bicycle Therapeutics股票(NASDAQ:BCYC)的股價下跌了12%,對於公司在過去五年中實現的真正穩健的長期回報,這幾乎沒有什麼影響。可以說,在這段時間裏,大多數人會對這個時間裏的106%的收益感到滿意。通常長期回報會給你一個比短期回報更好的業務質量的想法,當然這不一定意味着它現在便宜。
The past week has proven to be lucrative for Bicycle Therapeutics investors, so let's see if fundamentals drove the company's five-year performance.
過去一週證明了Bicycle Therapeutics股票投資人非常賺錢,那麼讓我們看看是否基本面帶動了公司的五年表現。
Because Bicycle Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.
因爲Bicycle Therapeutics在過去十二個月中虧損,所以我們認爲市場可能更關注營業收入和營業收入增長,至少現在是這樣的。不盈利公司的股東通常需要強勁的營收增長。一些公司願意推遲盈利,以更快的速度增長營收,但在這種情況下,希望有良好的銷售額增長來彌補收益的缺失。在過去的五年裏,Bicycle Therapeutics的營業收入增長了25%。這比大多數盈利前公司都要高。因此,在那個時候,股價以每年16%的速度增長,反映出這種表現。所以,看來買家們已經關注了強勁的營業收入增長。Bicycle Therapeutics似乎是一隻高增長股票-因此增長型投資者可能希望將其加入自選名單。
In the last 5 years Bicycle Therapeutics saw its revenue grow at 25% per year. That's well above most pre-profit companies. So it's not entirely surprising that the share price reflected this performance by increasing at a rate of 16% per year, in that time. So it seems likely that buyers have paid attention to the strong revenue growth. Bicycle Therapeutics seems like a high growth stock - so growth investors might want to add it to their watchlist.
Bicycle Therapeutics是一家知名公司,有很多分析師關注,意味着未來增長有一定的可見性。因此,我們建議查看這份顯示共識預測的免費報告。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240528/0-94feeaeeb37788df25d178626460d53c-0-ebbace58c26c4318ddf42888abf91964.png/big)
Bicycle Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts
Bicycle Therapeutics是一隻知名的股票,擁有大量的分析師覆蓋,預示着未來增長的一定可見性。因此,我們推薦查看這份免費報告,顯示共識預測。
A Different Perspective
不同的觀點
While the broader market gained around 28% in the last year, Bicycle Therapeutics shareholders lost 4.9%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 16% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Bicycle Therapeutics you should know about.
儘管整個市場在過去一年中上漲了近28%,但Bicycle Therapeutics的股東虧損了4.9%。即使是好股票的股價有時也會下跌,但我們希望在對業務的基本指標產生改善之前不會過於感興趣。但從積極的一面來看,長期股東已經賺了錢,在過去五年中每年增長了16%。如果基本數據繼續表明長期可持續增長,那麼目前的拋售可能是值得考慮的機會。我認爲從長期股價作爲業務績效的代理人來看是非常有趣的。但是要真正獲得洞察,我們需要考慮其他信息。考慮風險,比如。每個公司都有它們自己的風險,我們已經發現Bicycle Therapeutics的2個警告標誌,您應該知道它們。
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
如果您像我一樣,就不會希望錯過這份免費的內部人士正在購買的低估小市值股票列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。